NRx Pharmaceuticals (NASDAQ:NRXP) Announces Quarterly Earnings Results

NRx Pharmaceuticals (NASDAQ:NRXP) announced its quarterly earnings results on Friday. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01, FiscalAI reports. The company had revenue of $1.07 million for the quarter, compared to the consensus estimate of $25.57 million.

NRx Pharmaceuticals Price Performance

NASDAQ NRXP traded up $0.07 during trading hours on Friday, hitting $3.28. The company’s stock had a trading volume of 2,216,622 shares, compared to its average volume of 1,224,002. The company’s 50 day simple moving average is $2.43 and its two-hundred day simple moving average is $2.32. The company has a market cap of $108.47 million, a P/E ratio of -2.36 and a beta of 2.02. NRx Pharmaceuticals has a 12 month low of $1.62 and a 12 month high of $3.84.

Institutional Trading of NRx Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Anson Funds Management LP grew its position in NRx Pharmaceuticals by 50.3% in the 4th quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after acquiring an additional 1,018,853 shares during the last quarter. Commonwealth Equity Services LLC purchased a new stake in shares of NRx Pharmaceuticals during the 4th quarter worth $994,000. Vanguard Group Inc. raised its stake in NRx Pharmaceuticals by 18.3% in the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after buying an additional 82,781 shares during the last quarter. Geode Capital Management LLC raised its stake in NRx Pharmaceuticals by 27.9% in the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after buying an additional 37,598 shares during the last quarter. Finally, Two Sigma Investments LP raised its stake in NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after buying an additional 20,880 shares during the last quarter. 4.27% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on NRXP shares. Zacks Research upgraded shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Ascendiant Capital Markets upped their target price on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a “buy” rating in a research note on Monday, April 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Friday, May 8th. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price objective on shares of NRx Pharmaceuticals in a report on Monday, April 27th. Finally, D. Boral Capital reissued a “buy” rating and issued a $34.00 price target on shares of NRx Pharmaceuticals in a report on Tuesday, May 5th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $38.25.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.